SOHO Highlights: State of the Art and Next Questions
S

MPNs State of the Art: What Is the Response to Ruxolitinib vs. BAT? Can We Achieve CHR With Ropeginterferon Alpha-2b in PV? Can We Use Fedratinib in Treatment-Naïve MF?

By SOHO Highlights: State of the Art and Next Questions FEATURING Srdan Verstovsek
By SOHO Highlights: State of the Art and Next Questions FEATURING Srdan Verstovsek
158 views
February 3, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
05:20
Prithviraj Bose

When to Switch From Hydroxyurea to Ruxolitinib in PV

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
12:07
Douglas Tremblay

Monitoring Patients With MF: When to Switch Treatment

16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
09:46
Scripps MD Anderson Cancer Center

Ruxolitinib in Polycythemia Vera: Learnings From the RESPONSE Trial

Feat. D. Hermel
08:44
Krisstina Gowin

Management of Aquagenic Pruritis in Polycythemia Vera

11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
51:20
Jerry Spivak

Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…

53:01
PleXus Communications

Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis

Feat. R. Rampal
15:31
Icahn School of Medicine at Mount Sinai

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Feat. M. Kremyanskaya
11:09
Jeanne Palmer

Management of Clinical Manifestations in Myelofibrosis